UY29276A1 - Compuesto quimico y su uso - Google Patents

Compuesto quimico y su uso

Info

Publication number
UY29276A1
UY29276A1 UY29276A UY29276A UY29276A1 UY 29276 A1 UY29276 A1 UY 29276A1 UY 29276 A UY29276 A UY 29276A UY 29276 A UY29276 A UY 29276A UY 29276 A1 UY29276 A1 UY 29276A1
Authority
UY
Uruguay
Prior art keywords
prevention
preparation
treatment
chemical compound
diseases
Prior art date
Application number
UY29276A
Other languages
English (en)
Spanish (es)
Inventor
Dr Olaf Weber
Dr Carsten Schmeck
Dr Hilmar Bischoff
Dr Martina Wuttke
Dr Volkhart Li
Dr Alexandros Vakalopoulos
Dr Heike Gielen-Haertwig
Dr Michael Thutewohl
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of UY29276A1 publication Critical patent/UY29276A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UY29276A 2004-12-18 2005-12-20 Compuesto quimico y su uso UY29276A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung

Publications (1)

Publication Number Publication Date
UY29276A1 true UY29276A1 (es) 2006-07-31

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29276A UY29276A1 (es) 2004-12-18 2005-12-20 Compuesto quimico y su uso

Country Status (27)

Country Link
US (2) US8124775B2 (enExample)
EP (1) EP1828137B1 (enExample)
JP (1) JP5132317B2 (enExample)
KR (1) KR20070090248A (enExample)
AR (1) AR055011A1 (enExample)
AT (1) ATE555097T1 (enExample)
AU (1) AU2005315770B2 (enExample)
BR (1) BRPI0519602A2 (enExample)
CA (1) CA2591397A1 (enExample)
CU (1) CU23452B7 (enExample)
CY (1) CY1112887T1 (enExample)
DK (1) DK1828137T3 (enExample)
DO (1) DOP2005000259A (enExample)
ES (1) ES2384980T3 (enExample)
GT (1) GT200500377A (enExample)
IL (1) IL184008A (enExample)
MA (1) MA29100B1 (enExample)
MX (1) MX2007007188A (enExample)
NO (1) NO20073146L (enExample)
PE (1) PE20060767A1 (enExample)
PL (1) PL1828137T3 (enExample)
PT (1) PT1828137E (enExample)
RU (1) RU2393151C2 (enExample)
SI (1) SI1828137T1 (enExample)
TW (1) TW200635900A (enExample)
UY (1) UY29276A1 (enExample)
WO (1) WO2006063828A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
ATE520696T1 (de) * 2008-03-05 2011-09-15 Boehringer Ingelheim Int Tricyclische pyridinderivate, solche verbindungen enthaltende medikamente, ihre verwendung und verfahren zu ihrer herstellung
MA34007B1 (fr) 2010-02-19 2013-02-01 Boehringer Ingelheim Int Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation
US9187450B2 (en) * 2010-07-09 2015-11-17 Daiichi Sankyo Company, Limited Substituted pyridine compound
WO2012110599A1 (en) 2011-02-17 2012-08-23 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
US9150583B2 (en) 2011-08-17 2015-10-06 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US9321747B2 (en) 2012-01-06 2016-04-26 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128681A1 (de) * 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors

Also Published As

Publication number Publication date
PE20060767A1 (es) 2006-09-10
IL184008A0 (en) 2007-10-31
US20080255068A1 (en) 2008-10-16
GT200500377A (es) 2006-11-09
MX2007007188A (es) 2007-08-14
AU2005315770B2 (en) 2011-12-08
DOP2005000259A (es) 2006-11-15
KR20070090248A (ko) 2007-09-05
ATE555097T1 (de) 2012-05-15
AR055011A1 (es) 2007-08-01
IL184008A (en) 2012-03-29
BRPI0519602A2 (pt) 2009-02-25
JP5132317B2 (ja) 2013-01-30
CY1112887T1 (el) 2016-04-13
TW200635900A (en) 2006-10-16
EP1828137B1 (de) 2012-04-25
PL1828137T3 (pl) 2012-09-28
EP1828137A1 (de) 2007-09-05
AU2005315770A1 (en) 2006-06-22
MA29100B1 (fr) 2007-12-03
CU23452B7 (es) 2009-12-01
NO20073146L (no) 2007-09-18
PT1828137E (pt) 2012-07-04
RU2393151C2 (ru) 2010-06-27
SI1828137T1 (sl) 2012-08-31
WO2006063828A1 (de) 2006-06-22
US8124775B2 (en) 2012-02-28
US20120142728A1 (en) 2012-06-07
CA2591397A1 (en) 2006-06-22
DK1828137T3 (da) 2012-07-23
RU2007127127A (ru) 2009-01-27
ES2384980T3 (es) 2012-07-16
JP2008524145A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
CU23452B7 (es) Derivados de tetrahidroquinolina 4-cicloalquilo sustituidos
WO2009156462A3 (en) Organic compounds
WO2007115821A3 (en) Organic compounds
EA200702541A1 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
CL2008003940A1 (es) Compuestos derivados de morfolino pirimidina sustituida; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de cancer, enfermedades inflamatorias, enfermedades obstructivas de las vias aereas, enfermedades inmunes o enfermedades cardiovasculares.
EA201070247A1 (ru) Ингибиторы протеасом
NO345018B1 (no) Framgangsmåte for framstilling av organofluorforbindelser i alkoholholdige løsningsmidler.
WO2009140621A3 (en) Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
MX2009008486A (es) Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor.
WO2008003958A3 (en) Fused pyrimido compounds
EA201170772A1 (ru) Органические соединения
EP2078731A4 (en) ANTI-HB-EGF ANTIBODY AS PHARMACEUTICAL COMPOSITION CONTAINING ACTIVE SUBSTANCE
CL2007003765A1 (es) Compuestos derivados de 2-oxo-4-hidroxi-benzotiazol; procesode preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, bronquitis, asma y bronquiectasias.
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
ZA200610640B (en) Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
CR10052A (es) Proceso para la preparación de aminas
GB0508318D0 (en) Organic compounds
TW200745122A (en) New compounds I
EP2296665A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PREMATURE EJACULATION
CL2009000510A1 (es) Compuestos derivados de 1,3,5,6,7,8-hexahidro-furo[3,4-b]quinolina, inhibidores de cetp; proceso de preparacion de los compuestos; composicion farmaceutica; proceso de preparacion de la composicion; y uso en el tratamiento y/o prevencion de trastornos cardiovasculares y trastornos relacionados.
ATE496913T1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
UY28047A1 (es) Derivados de 7h-dibenzo(b,g)(1,5)dioxocin-5-ona y su uso
IN2012DN01245A (enExample)
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160726